Strategic Partnerships IMI has recent collaboration activity with Grifols Canada Therapeutics and Kiro Grifols, signaling openness to co-development and integrated solutions for secure drug delivery. This presents a pathway for joint offerings around tamper-evident devices and automated pharmacy workflows.

Hospitality to Home Health Expansion into the home health market via a partnership with Integrated Medical Systems indicates a channel strategy beyond traditional acute care. This creates sales opportunities for portable, secure delivery devices and compounding accessories suitable for home-based pharmacies.

Regulatory Compliance Holdings of ISO 13485 and relevant medical device directive certifications position IMI to target global customers seeking compliant, high-reliability tamper-evident solutions, reducing time-to-market for partner programs and institutional buyers.

Tamper-Evident leadership As an industry leader in tamper evident technologies for IV syringes, oral dispensers, and delivery systems, IMI can upsell advanced sterile adapters, caps, plugs, and venting needles to existing customers seeking enhanced security and safety in admixture and compounding workflows.

Scale and collaboration With a mid-market size and annual revenue in the lower tens of millions, IMI is well positioned to engage mid-to-large healthcare distributors and regional players for broader market penetration, leveraging existing partnerships and RFID/DoseID ecosystem interests for differentiated solutions.